CD274 and cancer: Considering serum ADA results to date from validated assays for ongoing clinical studies of dostarlimab used in accordance with common industry-tiered ADA testing approaches, we conclude that dostarlimab has an ADA incidence rate (2.5%) comparable to other anti-PD-(L)1 drugs, and treatment with dostarlimab elicits only a weak immune response in a small percentage of patients with cancer after one or more treatment cycles.